The purpose of this study is to determine the proportion of patients diagnosed with Lynch syndrome in colorectal cancer patients with the loss of staining by immunohistochemistry (IHC) of any of the mismatch repair (MMR) proteins. Besides, this study aims to test the specificity and the sensitivity of detecting microsatellite instability (MSI) by next-generation sequencing, and to find out the consistency between IHC and MSI in colorectal cancer patients in China. In addition, researchers want to analyze the clinical characteristics and germline mutation of Lynch syndrome in Chinese population.
1. Detect microsatellite instability (by next-generation sequencing and PCR capillary electrophoresis) and germline mutation (by next-generation sequencing) in probands. 2. Analyze the test outcome with clinical and family information to evaluate the germline mutation status preliminarily: likely pathogenic germline mutation, variant of uncertain significance, non-pathogenic germline mutation. 3. Verify the germline mutation in blood relatives whose proband has known likely pathogenic germline mutation or variant of uncertain significance. 4. Diagnose pathogenic germline mutation and non-pathogenic germline mutation based on clinical characteristics, family information and germline mutation test outcomes (including the outcomes of probands and blood relatives). Diagnose Lynch syndrome and the pathogenic germline mutation carriers in the included population. 5. Analyze the specificity and the sensitivity of detecting microsatellite instability (MSI) by next-generation sequencing; and analyze the consistency between IHC and MSI. 6. Analyze the clinical characteristics and germline mutation of Lynch syndrome in Chinese population.
Study Type
OBSERVATIONAL
Enrollment
311
Use next-generation sequencing to test germline mutation and microsatellite instability.
Fujian Medical University Cancer Hospital
Fuzhou, Fujian, China
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China
Yunnan Cancer Hospital
Kunming, Yunnan, China
Affiliated Hangzhou First People's Hospital
Hangzhou, Zhejiang, China
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
YUANYING
Hangzhou, Zhejinag, China
Pathogenic germline mutation
Pathogenic germline mutation using next-generation sequencing with a targeted panel.
Time frame: Upon completion of study, on average 2 years.
Variant of uncertain significance of germline mutation
Variant of uncertain significance of germline mutation using next-generation sequencing with a targeted panel.
Time frame: Upon completion of study, on average 2 years.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.